IDiyas

For the Inventor, By the Inventor

Milan, Italy

Sergio Penco

USPTO Granted Patents = 73 

 

Average Co-Inventor Count = 3.8

ph-index = 11

Forward Citations = 449(Granted Patents)


Inventors with similar research interests:


Location History:

  • Milano, IT (1990)
  • Milan, IT (1977 - 2012)

Company Filing History:

goldMedal25 out of 181 
 
Farmitalia Carlo Erba S.p.a.
 patents
silverMedal14 out of 343 
 
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
 patents
bronzeMedal10 out of 140 
 
Farmitalia Carlo Erba S.r.l.
 patents
4. 9 out of 46 
 
Societa' Farmaceutici Italia S.p.a.
 patents
5. 6 out of 97 
 
Pharmacia & Upjohn S.p.a.
 patents
6. 3 out of 14 
 
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
 patents
7. 2 out of 3 
 
Sigma-tau Research Switzerland S.a.
 patents
8. 1 out of 1 
 
Societa Farmaceutici Italia (farmitalia Carlo Erba S.p.a.)
 patent
9. 1 out of 1 
 
Istituo Nazionale Per Lo Studio E La Cura Dei Tumori
 patent
10. 1 out of 20 
 
Pharmacia S.p.a.
 patents
11. 1 out of 3 
 
Instituto Nazionale Per Lo Studio E La Cura Dei Tumori
 patents
12. 1 out of 1 
 
Istituto Nazional Per Lo Studio E La Cura Dei Tumori
 patent
13. 3 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1977-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Glycosaminoglycans
Antiangiogenic Activity
Retinoid Derivatives
Camptothecin Derivatives
Antitumor Activity
Anthracycline Glycosides
Chiral Synthesis
Site Specific Alkylating Agents
Biphenyl Derivatives
Natural Compounds
Cytostatic Agents
Chemosensitising Activity
73 patents (USPTO):Explore Patents
1. 8222231 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect (2012-07-17),
2. 8101793 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities (2012-01-24),
3. 8067555 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect (2011-11-29),
4. 7790700 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect (2010-09-07),
5. 7781416 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect (2010-08-24),
6. 7728039 - Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives (2010-06-01),
7. 7705012 - Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents (2010-04-27),
8. 7612081 - 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups (2009-11-03),
9. 7589099 - 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists (2009-09-15),
10. 7449495 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities (2008-11-11),
11. 7351714 - 7-imino derivatives of camptothecin having antitumor activity (2008-04-01),
12. 7105492 - Camptothecin derivatives having antitumor activity (2006-09-12),
13. 7084166 - Bis-heterocyclic compounds with antitumour and chemosensitising activity (2006-08-01),
14. 6887883 - Use of natural chrysanthone compounds having antiangiogenic activity (2005-05-03),
15. 6589939 - Camptothecin derivatives having antitumor activity (2003-07-08),

Title: The Innovator: Sergio Penco, Pioneering Antiangiogenic Solutions

Introduction:

Sergio Penco, a visionary inventor based in Milan, Italy, has made significant contributions to the field of pharmaceuticals with a total of 73 patents under his name. His groundbreaking work revolves around developing derivatives of partially desulfated glycosaminoglycans with antiangiogenic properties, free of anticoagulating effects, and retinoid derivatives with potent antiangiogenic, antitumoral, and proapoptotic activities.

Latest Patents:

Among his latest patents are derivatives of partially desulfated glycosaminoglycans that demonstrate antiangiogenic activity without anticoagulant effects, and retinoid derivatives with multifaceted therapeutic applications in angiogenesis-related conditions and cancer treatment.

Career Highlights:

Sergio Penco's expertise and innovation have been instrumental in companies such as Farmitalia Carlo Erba S.p.A. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. His pivotal role in these renowned pharmaceutical companies showcases his commitment to advancing medical science and improving patient outcomes through innovative solutions.

Collaborations:

Throughout his illustrious career, Sergio Penco has collaborated with distinguished professionals in the field, including Federico Maria Arcamone and Francesco Angelucci. Together, they have synergized their expertise to push the boundaries of pharmaceutical research and development, shaping the future of healthcare.

Conclusion:

In conclusion, Sergio Penco stands as a leading figure in the realm of pharmaceutical innovation, spearheading advancements in antiangiogenic therapies and cancer treatments. His prolific career, marked by numerous patents and successful collaborations, underscores his relentless pursuit of excellence and his unwavering dedication to revolutionizing the medical landscape for the betterment of society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…